Cargando…

The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols

One of the most frequent genes affected in pediatric ALL is the CDKN2A/2B gene, acting as a secondary cooperating event and playing an important role in cell-cycle regulation and chemosensitivity. Despite its inclusion in combined CNA (copy-number alterations) classifiers, like the IKZF1plus entity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ampatzidou, Mirella, Papadhimitriou, Stefanos I., Paisiou, Anna, Paterakis, Georgios, Tzanoudaki, Marianna, Papadakis, Vassilios, Florentin, Lina, Polychronopoulou, Sophia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178600/ https://www.ncbi.nlm.nih.gov/pubmed/37174980 http://dx.doi.org/10.3390/diagnostics13091589

Ejemplares similares

Copy Number Alteration Profile Provides Additional Prognostic Value for Acute Lymphoblastic Leukemia Patients Treated on BFM Protocols
por: Ampatzidou, Mirella, et al.
Publicado: (2021)

P821: LATE ONSET AND/OR LONG LASTING NEUTROPENIA IN CHILDHOOD: CLINICAL AND HEMATOLOGICAL CHARACTERISTICS AND OUTCOMES
por: Kelaidi, C., et al.
Publicado: (2022)

Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen
por: Yu, Hui, et al.
Publicado: (2022)

Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP‐BFM acute lymphoblastic leukemia protocol
por: Jung, Mareike, et al.
Publicado: (2020)

Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis
por: Kostopoulos, I V, et al.
Publicado: (2017)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia
por: Genescà, E., et al.
Publicado: (2018)

RUNX1 mutation has no prognostic significance in paediatric AML: a retrospective study of the AML-BFM study group
por: Sendker, Stephanie, et al.
Publicado: (2023)

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A
por: Tu, Q, et al.
Publicado: (2018)

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas
por: Marker, Daniel F., et al.
Publicado: (2020)

The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG
por: Dalle, Jean-Hugues, et al.
Publicado: (2020)

Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma
por: Ma, Sirui, et al.
Publicado: (2020)

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran
por: HAYATI, Hadi, et al.
Publicado: (2018)

Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma
por: Wang, Haiwei, et al.
Publicado: (2021)

CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients
por: Xu, Na, et al.
Publicado: (2015)

Gene Deletions and Prognostic Values in B-Linage Acute Lymphoblastic Leukemia
por: Fang, Qiuyun, et al.
Publicado: (2021)

Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis
por: Ortiz, Berenice, et al.
Publicado: (2014)

PB1733: LONG-TERM FOLLOW-UP FOR PATIENTS WITH T CELL LYMPHOBLASTIC LYMPHOMA/ ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED MODIFIED BFM PROTOCOLS
por: Gao, Yan, et al.
Publicado: (2023)

P1556: HYPER -FERRITINEMIA IN PEDIATRIC ONCOLOGY PATIENTS SECONDARY TO TREATMENT: DIAGNOSTIC APPROACH AND OUTCOME
por: Grafakos, I., et al.
Publicado: (2022)

The Yin and Yang-Like Clinical Implications of the CDKN2A/ARF/CDKN2B Gene Cluster in Acute Lymphoblastic Leukemia
por: González-Gil, Celia, et al.
Publicado: (2021)

miR-125b predicts childhood acute lymphoblastic leukaemia poor response to BFM chemotherapy treatment
por: Piatopoulou, Despina, et al.
Publicado: (2017)

Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Xu, Na, et al.
Publicado: (2016)

Germline hemizygous deletion of CDKN2A–CDKN2B locus in a patient presenting with Li–Fraumeni syndrome
por: Chan, Sock Hoai, et al.
Publicado: (2016)

Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia
por: Zhou, Xueyan, et al.
Publicado: (2018)

CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia
por: Jang, Woori, et al.
Publicado: (2019)

ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol
por: Wang, Yu, et al.
Publicado: (2018)

Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia
por: Schieck, Maximilian, et al.
Publicado: (2020)

The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis
por: Xing, X, et al.
Publicado: (2013)

CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma
por: Luo, Jun-peng, et al.
Publicado: (2021)

The functional role of inherited CDKN2A variants in childhood acute lymphoblastic leukemia
por: Li, Chunjie, et al.
Publicado: (2021)

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas
por: Sievers, Philipp, et al.
Publicado: (2020)

CDKN2A Deletion Leading to Hematogenous Metastasis of Human Gastric Carcinoma
por: Qiao, Juanli, et al.
Publicado: (2021)

CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review
por: Yuile, Alexander, et al.
Publicado: (2023)

Correction: CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma
Publicado: (2022)

Outcome of ALL With ALL-BFM-95 Protocol in Nepal
por: Sharma Poudyal, Bishesh, et al.
Publicado: (2023)

Childhood Acute B-Lineage Lymphoblastic Leukemia With CDKN2A/B Deletion Is a Distinct Entity With Adverse Genetic Features and Poor Clinical Outcomes
por: Feng, Jing, et al.
Publicado: (2022)

Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia
por: Yao, Qiu-Mei, et al.
Publicado: (2016)

Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report
por: Maurer-Granofszky, Margarita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s39lrjfedk94o55p1983d5j3gk